Webinar: Redefining Excellence in the Era of AI and Human Collaboration
Discover your potential savings with our ROI Calculator
Webinar: Elevating Customer Experience Through Quality
Self-guided Product Tours
Product Demo Videos
Pricing
Recent Analyst Insights
Featured Analyst Insights
2026 Gartner® Magic Quadrant™ for Quality Management System Software
Recent Blogs
Recent Infographics
Recent Case Studies
Featured Case Study
ComplianceQuest Medical Devices QMS Success Stories eBook
Recent Checklists
Featured Checklist
Complaint Handling Process for MedTech and Life Science Companies
Course Offerings
Recent CQ Guides
Datasheets
Brochures
Demo Center
Videos
Podcasts
Recent Webinars
Webinar
Unlocking the Value of Complaints
Recent Whitepapers
Whitepaper
Why You Need to Digitally Transform Your QMS
Compliance
Toolkits
Infographic
Safety Technology Trends to Watch in 2023 (Infographic)
Recent Toolkits
Events and Webinars
Events
Upcoming Webinars
Featured Event
PDA/FDA Joint Regulatory Conference 2026
14 Sep, 2026
Washington, DC
About
About ComplianceQuest
ComplianceQuest is the #1 AI-powered Quality, Risk, and Compliance (QRC) platform that connects Product, Quality, Manufacturing, People, Suppliers and Customers in a single system.
Built on Salesforce, the platform delivers end-to-end visibility, AI-driven intelligence, and enterprise-scale execution, enabling organizations to manage risk, ensure regulatory compliance, and turn quality into a driver of growth.
Meet the Leadership Team
Careers
Where Your Career Takes Flight: Join our dynamic team and be part of an innovative, collaborative and rewarding workplace culture.
Corporate Citizenship
Impact Through Action: How the ComplianceQuest team supports social causes and community engagement
Customers & Testimonials
Newsroom
The Pulse of ComplianceQuest: Our newsroom shares stories of innovation, progress, and change
Partners
Stronger Together: How our partnerships drive success and innovation
Upcoming Events
Medical device software plays a critical role in product safety, performance, and regulatory compliance. Manufacturers must manage software risks, validation, documentation, cybersecurity, and changes throughout the device lifecycle while meeting applicable FDA requirements and industry standards.
Software in a Medical Device (SiMD) is software embedded inside a physical medical device to control its function, as opposed to Software as a Medical Device (SaMD), which runs independently on general-purpose hardware. SiMD can serve a diagnostic, monitoring, therapeutic, or control-related role, but not all embedded software is automatically regulated as a medical device, the software's intended function determines that. Whether SiMD is subject to FDA oversight, and at what documentation level, depends on the risk the software's failure could pose to the patient, user, or others in the environment of use.
Software in a Medical Device (SiMD) refers to software that is built into, and operates as an integral part of, a physical medical device's hardware. Unlike standalone software that runs independently on a computer or mobile phone, SiMD only exists and functions as part of the device it's embedded in, it has no purpose or use outside of that hardware.
SiMD's role within a device can be diagnostic (interpreting a signal to support a diagnosis), monitoring (tracking a physiological parameter over time), therapeutic (actively delivering a treatment, as with the insulin pump), or control-related (directing the mechanical or electronic operation of the device). Not all embedded software automatically counts as regulated medical-device software, what matters is the software's intended function.
SiMD operates through a defined sequence that runs from data input to device output, generally following this process:
SaMD vs. SiMD in the same clinical area: The same clinical function can involve either SaMD or SiMD, depending on how the software is deployed. Software embedded in an imaging system to control image capture is SiMD, it exists only as part of that hardware. A separate application that independently analyzes the resulting image, running on a general-purpose computer, for instance, without controlling the imaging hardware itself, may be SaMD instead. The distinction isn't the clinical task; it's whether the software is inseparable from a specific piece of hardware or capable of functioning independently.
Software as a Medical Device (SaMD) and Software in a Medical Device (SiMD) are often confused because both involve medical software, but the distinction between them shapes everything from how they're built to how they're regulated. The core difference comes down to hardware dependency: SaMD runs independently of any specific medical hardware, while SiMD is embedded in, and inseparable from, a physical device.
Classifying SiMD isn't a separate exercise from classifying the device it's part of. The software is evaluated as a component of the device's overall risk profile. The classification of SiMD depends on the medical device's intended use, its risk level, the specific function the software performs, and the potential harm that could result if the software fails.
Main classification factors include the FDA device class the overall device falls into (Class I, II, or III), the specific product code assigned to the device type, and the regulatory submission pathway that applies, such as 510(k) clearance, De Novo classification, or Premarket Approval (PMA). Each of these factors influences how much software documentation a submission needs to include.
Relevant FDA guidance: The FDA's guidance document Content of Premarket Submissions for Device Software Functions (finalized June 14, 2023) governs how software documentation should be prepared and evaluated for premarket submissions that include a device software function. This guidance replaced the FDA's earlier "Level of Concern" framework, which had classified software as Minor, Moderate, or Major.
Basic and Enhanced Documentation Levels: Under the current guidance, the FDA uses a risk-based approach that sorts submissions into one of two Documentation Levels (Basic or Enhanced), rather than the previous three-tier system. Basic Documentation applies to software where a failure would not be expected to result in a hazardous situation with a probable risk of death or serious injury.
An important clarification: FDA device class (I, II, III) reflects the overall device's regulatory risk category. IEC 62304 software safety classification (A, B, C) reflects the potential for the software itself to contribute to a hazardous situation, independent of the device's regulatory pathway. IMDRF SaMD risk categories (I–IV) apply specifically to standalone SaMD products, based on the significance of the information the software provides and the state of the healthcare situation.
SiMD risk matters in a way that's distinct from ordinary software risk: because the software is embedded directly in a physical device, a software failure can directly affect the device's mechanical or electronic behavior, and, in turn, patient safety, in ways that standalone software failures typically cannot.
Functional and safety risk. A software defect in SiMD can cause the device to behave incorrectly — delivering an incorrect dose, misreading a sensor, or failing to trigger a needed alarm. Because the software directly controls physical device behavior, these failures translate immediately into a physical safety event rather than remaining a data or display error.
Cybersecurity risk. Connected and embedded devices are increasingly exposed to cybersecurity threats that can compromise device functionality, not just data confidentiality. FDA's current guidance explicitly considers whether device functionality could be intentionally or unintentionally compromised through inadequate cybersecurity controls, and expects that risk to be evaluated alongside conventional software hazards.
Change management risk. Because SiMD is inseparable from its hardware, even a small software update can require re-verifying the entire device, including the hardware-software interface, rather than being evaluated as an isolated software release. Poorly managed change control is a common source of downstream compliance and safety issues.
Verification and validation gaps. Incomplete testing of the hardware-software interface, or validation performed only on the software in isolation rather than the complete device in representative conditions, is a recurring source of risk that regulators scrutinize closely during premarket review and post-market surveillance.
Documentation and traceability risk. Because Documentation Level determinations, risk management files, and design history records must all align, gaps in traceability between requirements, identified hazards, and verification/validation evidence create regulatory risk even when the software itself performs correctly.
Yes, when the software performs a device software function as part of a regulated medical device, it's evaluated as part of that device's overall premarket submission — it isn't reviewed as a separate product the way standalone SaMD often is. Whether the software requires Basic or Enhanced Documentation depends on the risk a software failure could pose to the patient or user.
SiMD generally follows a structured lifecycle aligned with standards like IEC 62304, covering planning, requirements analysis, architectural and detailed design, implementation, verification, and release, followed by ongoing maintenance. Because the software is embedded in hardware, the lifecycle also has to account for hardware-software integration and device-level validation at each relevant stage.
Common challenges include managing the hardware-software interface reliably, maintaining traceability across requirements, risks, and test evidence, and re-validating the complete device whenever the software changes. Teams also often struggle with correctly scoping cybersecurity risk for embedded, connected devices that weren't originally designed with network exposure in mind.
Because SiMD functions as one system with its hardware, manufacturers should evaluate every software change against the device's existing risk management file and determine whether the change affects previously validated functionality. Regression testing and updated traceability documentation are typically required even for changes that seem isolated to the software.
No. SiMD is submitted as part of the medical device's own premarket submission, since the software has no independent existence or function apart from the hardware it controls. The software documentation becomes one component of that single device submission, at whichever Documentation Level applies.
Post-market software updates typically require the manufacturer to assess whether the change is significant enough to require a new or supplemental regulatory submission, based on how the change affects the device's safety or effectiveness. Manufacturers are also expected to maintain change control records and re-validate affected functionality even for updates that don't trigger a new submission.
Yes, AI/ML components can be embedded within SiMD, though they introduce additional considerations around how the algorithm's behavior is validated and monitored over time, especially if it's designed to adapt after deployment. Regulatory mechanisms like Predetermined Change Control Plans (PCCPs) have been introduced specifically to give manufacturers a defined pathway for managing AI/ML updates without requiring a new submission for every change.
Why MedTech Companies Must Have a Well-Documented Cybersecurity Risk Mitigation Game Plan
Understanding AI, ML and more in Software as Medical Device (SaMD) with a GMP ISO Expert
Speed of Digital Health: Opportunities and Challenges in Software as a Medical Device (SaMD)
Please confirm your details
By submitting this form you agree that we can store and process your personal data as per our Privacy Statement. We will never sell your personal information to any third party.
Enter Captcha